At 6.0% CAGR, the North America Intracranial pressure monitoring Devices Market is projected to be worth US$ 960.14 million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the North America intracranial pressure monitoring devices market was valued at US$ 715.80 million in 2023 and is expected to reach US$ 960.14 million by 2028, registering a CAGR of 6.0% from 2023 to 2028. Increasing prevalence of neurological diseases and rising incidence of traumatic brain injuries (tbis) are the critical factors attributed to the North America intracranial pressure monitoring devices market expansion.                    

Traumatic brain injury (TBI) often occurs due to severe sports injuries or road accidents. Four main TBI types exist concussion, contusion, penetrating injury, and anoxic brain injury. The symptoms of TBI depend on the extent of damage to the brain. Further, a report by the Brain Injury Association of New York State (BIANYS) estimated that 35.2% of the total TBI cases in the US are due to falls, 17.3% due to motor vehicle traffic crashes, 16.5% due to struck by/against events, and 10% due to assaults. CDC estimates that 1.6–3.8 million sports and recreation-related concussion cases occur annually in the US. 10% of all contact sports athletes sustain concussions every year. Brain injuries cause more fatalities than any other sports injury, ranging from 65% to 95% of all the casualties in football. Thus, the rising incidence of traumatic brain injuries fuels the growth of the North America intracranial pressure (ICP) monitoring devices market.

On the contrary, limitations associated with ICP monitors hurdles the growth of North America intracranial pressure monitoring devices market. 

Based on offering, the North America intracranial pressure monitoring devices market is segmented into product & systems, solutions & platform, and services. The products and systems held 70.4% market share in 2023, amassing US$ 503.78 million. It is projected to garner US$ 668.53 million by 2028 to expand at 5.8% CAGR during 2023–2028.

Based on type, the North America intracranial pressure monitoring devices market is segmented into invasive and non-invasive. The invasive segment held 79.2% market share in 2023, amassing US$ 566.94 million. It is projected to garner US$746.51 million by 2028 to expand at 5.7% CAGR during 2023–2028.

Based on applications, the North America intracranial pressure monitoring devices market is segmented into traumatic brain injuries, reye’s syndrome, non-traumatic bleeds, hydrocephalus, space-occupying lesions, cerebral oedema, and others. The traumatic brain injuries held 33.7% market share in 2023, amassing US$ 241.55 million. It is projected to garner US$ 318.72 million by 2028 to expand at 5.7% CAGR during 2023–2028.

Based on end user, the North America intracranial pressure monitoring devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held 50.8% market share in 2023, amassing US$ 363.84 million. It is projected to garner US$ 480.82 million by 2028 to expand at 5.7% CAGR during 2020–2028.

Based on country, the North America intracranial pressure monitoring devices market is segmented into the US, Canada, and Mexico. Our regional analysis states that the US captured 84.5% market share in 2023. It was assessed at US$ 604.78 million in 2023 and is likely to hit US$ 804.98 million by 2028, exhibiting a CAGR of 5.9% during the forecast period.     

Key players dominating the North America intracranial pressure monitoring market are Natus Medical Inc; RAUMEDIC AG; Sophysa SA; Integra LifeSciences Holdings Corp; Medtronic Plc; Braincare Desenvolvimento e Inovacao Tecnologica SA; NovaSignal Corp; Digitimer Ltd; and  Longeviti Neuro Solutions LLC among others.   

• In Aug-2023, Integra LifeSciences announced an immediate global voluntary removal of its CereLink intracranial pressure monitors after receiving reports from some customers that their readings were out of range. The Princeton, N.J.-based, medical device manufacturer is investigating the problem.
• In Dec-2019, Raumedic launched a new home-use device, Raumed Home ICP, for monitoring intracranial pressure (ICP). The product was developed for patients suffering from hydrocephalus, a condition where excessive amounts of cerebrospinal fluid (CSF) accumulate in the brain. The device has recently received a CE marking.  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com